Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)1990-472XФедеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации1079110.18499/1990-472X-2025-26-1-64-70A STUDY OF SPECSIN IN OBESE CHILDREN ON THE BACKGROUND OF THERAPY WITH A GLUCAGON-LIKE PEPTIDE-1 ANALOGChubarovTimofeychubarov25@yandex.ruSharshovaOlgagenvgma@yandex.ruZhdanovaOlgaolga.vr9@yandex.ruBuzulukinaInnabuzulukina@gmail.comIzmalkovaAlinaaizmalkova@bk.ruGaldaOlgagalda.ol@yandex.ru28032025261647031032025Copyright © 2025, Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)2025<p>Relevance. Recently, the incidence of obesity among the child population has been steadily increasing. Adipokine hormones, which affect the level of metabolic processes, play a significant role in the development of this pathology. One of these substances is spexin, which is currently being considered as a possible marker of cardiometabolic risk in obese patients.</p> <p>Goal. To study the level of specsin in obese children using a glucagon-like peptide-1 receptor agonist liraglutide.</p> <p>Materials and methods. A study of the level of spexin was conducted in obese children before the start of therapy and 3 months after the use of liraglutide. The level of spexin was determined by enzyme immunoassay using a set of Spexin/Neuropeptide Q reagents.</p> <p>The results obtained and their discussion. The study included 23 patients with an established diagnosis of constitutionally exogenous obesity of II-III degrees and morbid obesity, and a group of patients with 20 children over 12 years of age with a normal BMI was taken for comparison.As a result of our study, it was revealed that the level of spexin in obese children was higher than in healthy children, but at the same time it was within the reference values. According to the results of our studies, when repeated treatment 3 months after the start of liraglutide therapy, there are significant differences in the level of spexin not identified.However, significant changes in body weight were noted in the study group (before the start of therapy, the average value was 98 kg, after 3 months this indicator was 90 kg).</p> <p>Conclusion. No data were found on the effect on the level of spexin in children during complex therapy using a glucagon-like peptide-1 receptor agonist liraglutide. At the same time, a positive effect of therapy was observed, which manifested itself in a decrease in body weight in the study group of patients.</p>Spexinobesityliraglutidechildrenспексиножирениелираглутиддети.1.1. Васюкова О.В., Окороков П.Л., Малиевский О.А., Неймарк А.Е., Зорин Е.А., Яшков Ю.И., Бурмицкая Ю.В., Копытина Д.А., Безлепкина О.Б., Петеркова В.А. Клинические рекомендации «Ожирение у детей». Ожирение и метаболизм. 2024;21(4):439-453. https://doi.org/10.14341/omet131942.2. Ожирение и избыточная масса тела. Информационный бюллетень ВОЗ. https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight3.3. Т. В. Чубаров, И. В. Гребенникова, О. А. Жданова и др. Патофизиологические особенности гормональной активности жировой ткани при ожирении у детей. Вестник новых медицинских технологий. – 2023. – Т. 30, № 3. – С. 82-86. – DOI 10.24412/1609-2163-2023-3-82-86.4.4. Pekal Y, Özhan B, Enli Y, Özdemir ÖMA, Ergin H. Cord Blood Levels of Spexin, Leptin, and Visfatin in Term Infants Born Small, Appropriate, and Large for Gestational Age and Their Association with Newborn Anthropometric Measurements. J Clin Res Pediatr Endocrinol. 2022 Dec 1;14(4):444-452. doi: 10.4274/jcrpe.galenos.2022.2022-4-24. Epub 2022 Jul 21. PMID: 35859814; PMCID: PMC9724059.5.5. Behrooz M, Vaghef-Mehrabany E, Maleki V, Pourmoradian S, Fathifar Z, Ostadrahimi A. Spexin status in relation to obesity and its related comorbidities: a systematic review. J Diabetes Metab Disord. 2020 Nov 7;19(2):1943-1957. doi: 10.1007/s40200-020-00636-8. PMID: 33520870; PMCID: PMC7843752.6.6. Xiaotong Sun, , Ziwei Yu, Shengdan Pu, Xinyuan Gao. The role of spexin in energy metabolism. Peptides 2023 Jun:164:170991. doi: 10.1016/j.peptides.2023.170991.7.7. S. Kumar, J. Hossain, N. Nader et al. Decreased circulating levels of Spexin in obese children. The Journal of Clinical Endocrinology and Metabolism. –2016. – Volume 101, № 7. – P. 2931-2936.8.8. Maciej Sassek , Pawel A Kolodziejski , Dawid Szczepankiewicz , Ewa Pruszynska-Oszmalek. Spexin in the physiology of pancreatic islets-mutual interactions with insulin. Endocrine. 2019 Mar;63(3):513-519.doi: 10.1007/s12020-018-1766-2.Epub 2018 Sep 289.9. Abdelkrim Khadir , Sina Kavalakatt, Dhanya Madhu, Sriraman Devarajan, Jehad Abubaker , Fahd Al-Mulla et al. Spexin as an indicator of beneficial effects of exercise in human obesity and diabetes. 2020 Jun 30;10(1):10635. doi: 10.1038/s41598-020-67624-z10.10. İbrahim Türkel, Gülsün Memi, Burak Yazgan. Impact of spexin on metabolic diseases and inflammation: An updated minireview. Exp Biol Med (Maywood) 2022 Apr;247(7):567-573. Doi 10.1177/15353702211072443. Epub 2022 Jan 22.11.11. Nouran Y Salah, Dina Abu Zeid, Rania N Sabry, Reham F Fahmy, Mona A El Abd, Eman Awadallah at al. Circulating spexins in children with obesity: relation to cardiometabolic risk. Eur J Clin Nutr. 2022 Jan;76(1):119-125. doi: 10.1038/s41430-021-00912-7. Epub 2021 Apr 13.12.12. Болотова НВ, Белоусова МС, Чередникова КА, Филина НЮ, Поляков ВК, Аверьянов АП. Комплексный подход к терапии ожирения у детей подросткового возраста // Вестник терапевта. - 2023. – Т. 58. - № 3. - С. 34-58. [Bolotova NV, Belousova MS, Cherednikova KA, Filina NY, Polyakov VK, Averyanov AP. A comprehensive approach to the treatment of obesity in adolescent children. Vestnik terapevta. 2023;58(3):34-58. (In Russ.).]13.13. Muzurović EM, Volčanšek Š, Tomšić KZ, Janež A, Mikhailidis DP, Rizzo M, Mantzoros CS. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease – Current Evidence. Journal of Cardiovascular Pharmacology and Therapeutics. 2022;27. doi:10.1177/1074248422114637114.14. Kumar S, Hossain MJ, Javed A, Kullo IJ, Balagopal PB. Relationship of circulating spexin with markers of cardiovascular disease: a pilot study in adolescents with obesity. Pediatr Obes. 2018;13(6):374–380. doi: 10.1111/ijpo.12249. [DOI] [PMC free article] [PubMed] [Google Scholar]15.15. Nida Gulderen Kalay Senturk, Aydilek Dagdeviren Cakir, Zeynep Yildiz Yildirmak, Ahmet Ucar. Assessment of Serum Spexin Levels in Obese Adolescents with Metabolic Syndrome Antecedents: Preliminary Results. Horm Res Paediatr. 2021;94(9-10):343-352. doi: 10.1159/000521180. Epub 2021 Nov 26.16.16. Hodges SK, Teague AM, Dasari PS, Short KR. Effect of obesity and type 2 diabetes, and glucose ingestion on circulating spexin concentration in adolescents. Pediatr Diabetes. 2018;19(2):212–216. doi: 10.1111/pedi.12549. [DOI] [PubMed] [Google Scholar]17.17. Kolodziejski PA, et al. Serum levels of spexin and kisspeptin negatively correlate with obesity and insulin resistance in women. Physiol Res. 2018;67(1):45–56. doi: 10.33549/physiolres.933467.